We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medidata's Payment Solution to Make Reimbursements Easy
Read MoreHide Full Article
Medidata Solutions Inc recently introduced Medidata Payments, a cloud-based payment technology and an add-on to the company’s’ leading Medidata Clinical Cloud.
With this launch, the company is set to simplify the reimbursement procedure in the space of clinical research by addressing all the probable challenges like erroneous calculations along with inaccurate and delayed payments.
Medidata Payments offers a precise payment solution, unifying pre-payments, holdbacks, divide payments among different payees, payments in multiple currencies and accruals. The platform also provides clinical trial sponsors with easy solutions that identifies and calculates withholding-tax, captures indirect tax and performs worldwide disimbursement.
The Payment solution works in three major steps -- managing of contract requirements, recording the costs generated by the trial data and disbursing payments to the investigative sites across multiple clinical researches worldwide.
Medidata’s new launch is likely to revolutionize the clinical trial payment platform, fortifying partnerships between sponsors, contract research organizations and clinical investigation sites. The tool is also likely to be beneficial to the sponsors who conduct multiple trials globally using more than 125 different currencies.
Notably, Medidata Solutions has 17 out of the top 25 global Pharma companies as enterprise customers, demonstrating its accomplishments in the space. Medidata Payments is likely to fortify the company’s position as it will streamline trial processes to a considerable extent.
Zacks Rank & Key Picks
Currently, Medidata Solutions has a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical instrument sector include Foundation Medicine Inc. , Omnicell Inc (OMCL - Free Report) and Invitae Corporation . While Foundation Medicine and Omnicell sport a Zacks Rank #1 (Strong Buy), Invitae Corporation holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Medidata's Payment Solution to Make Reimbursements Easy
Medidata Solutions Inc recently introduced Medidata Payments, a cloud-based payment technology and an add-on to the company’s’ leading Medidata Clinical Cloud.
With this launch, the company is set to simplify the reimbursement procedure in the space of clinical research by addressing all the probable challenges like erroneous calculations along with inaccurate and delayed payments.
Medidata Payments offers a precise payment solution, unifying pre-payments, holdbacks, divide payments among different payees, payments in multiple currencies and accruals. The platform also provides clinical trial sponsors with easy solutions that identifies and calculates withholding-tax, captures indirect tax and performs worldwide disimbursement.
The Payment solution works in three major steps -- managing of contract requirements, recording the costs generated by the trial data and disbursing payments to the investigative sites across multiple clinical researches worldwide.
MEDIDATA SOLUTN Price and Consensus
MEDIDATA SOLUTN Price and Consensus | MEDIDATA SOLUTN Quote
Medidata’s new launch is likely to revolutionize the clinical trial payment platform, fortifying partnerships between sponsors, contract research organizations and clinical investigation sites. The tool is also likely to be beneficial to the sponsors who conduct multiple trials globally using more than 125 different currencies.
Notably, Medidata Solutions has 17 out of the top 25 global Pharma companies as enterprise customers, demonstrating its accomplishments in the space. Medidata Payments is likely to fortify the company’s position as it will streamline trial processes to a considerable extent.
Zacks Rank & Key Picks
Currently, Medidata Solutions has a Zacks Rank #3 (Hold).
Better-ranked stocks in the medical instrument sector include Foundation Medicine Inc. , Omnicell Inc (OMCL - Free Report) and Invitae Corporation . While Foundation Medicine and Omnicell sport a Zacks Rank #1 (Strong Buy), Invitae Corporation holds a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>